Table 4.
CAR-T cell-based treatments authorised in Italy under HE (Source Database AIFA-Istituto Superiore di Sanità, Italy).
| 2021 | ||||||
| Age | Target | Derived From | Medicinal Product | Treatment Outcome | Degree of Disease | Donor |
| 18 | ALL-B | HSCT | Allogeneic CD19 CAR-T cells | Unknown | Risk of recurrence | HLA identical |
| 2 | ALL-B | HSCT | Allogeneic CD19 CAR-T cells | Unknown | Resistant to chemotherapy | HLA identical |
| 11 | ALL-B | HSCT | Allogeneic CD19 CAR-T cells | Unknown | Multiple relapses and resistant | HLA identical |
| 20 | ALL-B | HSCT | Allogeneic CD19 CAR-T cells | Unknown | Refractory to multiple treatments | HLA identical |
| 6 | ALL-B | HSCT | Allogeneic CD19 CAR-T cells | Positive | Relapse | HLA identical familial |
| 29 | ALL-B | HSCT | Allogeneic CD19 CAR-T cells | Unknown | Fifth time reoffend | HLA identical |
| 2022 | ||||||
| Age | Target | Derived from | Medicinal Product | Treatment Outcome | Degree of Disease | Donor |
| 11 | Neuroblastoma | HSCT | Allogeneic GD2 CAR-T cells | Unknown | Multi-treated and relapsed | HLA identical |
| 12 | ALL-B | HSCT | Allogeneic CD19 CAR-T cells | Unknown | Relapsed for the third time | HLA identical |
| 8 | ALL-B | 1°maintenance therapy | Allogeneic CD19 CAR-T cells | Unknown | Relapsed for the first time | HLA identical |
| 17 | ALL-B | HSCT | Allogeneic CD19 CAR-T cells | Positive | Relapse | HLA identical |
| 4 | ALL-B | 1°maintenance therapy | Allogeneic CD19 CAR-T cells | Positive | Relapsed and associated with Down syndrome | HLA identical |
| 26 | ALL-B | HSCT and autologous CAR-T therapy | Allogeneic CD19 CAR-T cells | Positive | Relapse | HLA identical |
| 8 | Neuroblastoma | HSCT | Allogeneic GD2 CAR-T cells | Positive | Recurrent, metastatic, and refractory | HLA identical |
| 9 | ALL-B | HSCT | Allogeneic CD19 CAR-T cells | Positive | Relapsed | HLA identical intrafamilial |
| 33 | ALL-B | HSCT | Allogeneic CD19 CAR-T cells | Positive | Relapsed | HLA identical |
| 6 | Neuroblastoma | HSCT | Allogeneic GD2 CAR-T cells | Unknown | Metastatic | HLA identical familial |
| 34 | ALL-B | HSCT | Allogeneic CD19 CAR-T cells | Unknown | Relapse | HLA identical familial |
| 2023 | ||||||
| Age | Target | Derived from | Medicinal Product | Treatment Outcome | Degree of Disease | Donor |
| 27 | ALL-B | HSCT from MUD | Allogeneic CD19 CAR-T cells | Positive | Relapse | HLA compatible (MUD) |
| 5 | Neuroblastoma | Chemotherapy and autologus CS reinfusion | Allogeneic GD2 CAR-T cells | Unknown | Metastatic and refractory | |
| 8 | ALL-B | HSCT | Autologous CD19 CAR-T cells | Positive | Relapse | HLA identical familial |
| 4 | Neuroblastoma | Second-line chemotherapy | Autologous GD2 CAR-T cells | To be defined | Recurrent, metastatic, and refractory | |
| 8 | Lupus Erythematosus | Worsening of the clinical condition | Autologous CD19 CAR-T cells | To be defined | Systematic and resistant | |
| 9 | Neuroblastoma | Autologous GD2 CAR-T cells | To be defined | Recurrent, metastatic, and refractory | ||
| 10 | Neuroblastoma | Autologous GD2 CAR-T cells | To be defined | Recurrent, metastatic, and refractory | ||
| 7 | Neuroblastoma | Autologous GD2 CAR-T cells | To be defined | Recurrent, metastatic, and refractory | ||
| 6 | ALL-B | HSCT | Allogeneic CD19 CAR-T cells | To be defined | Relapse | HLA identical |